Arpit Vyas, MD, Dishman Pharma aims at working with EBITDA margins not below USD 25-30 percent and expects to pare down the company debt by Rs 70-80 crore this calendar year.
first published: Oct 3, 2013 11:50 am
A collection of the most-viewed Moneycontrol videos.

Live: Nifty reclaims 25,900, snaps 3-day losing streak; rupee falls to fresh low | Closing Bell

Live: Can Nifty snap 3-day losing streak after Fed's policy outcome? | Opening Bell

Live: Nifty slips below 24,800 as breadth weakens; SMIDs underperform | Closing Bell

Live: Nifty eyes broader market volatility, FOMC outcome for next cues | Opening Bell
You are already a Moneycontrol Pro user.

